How would you approach frontline treatment for a metastatic non-squamous NSCLC patient with MET amplification and a concurrent KRAS mutation?   

There are a couple of components to this question: first, what is the role of TKI therapy in MET amplified lung cancer, and second, what is a clinician to do when there are more than one "driver" mutations (ie KRAS and MET amp in this case)? Regarding the first question, this is somewhat timely in t...